Recent News

• 06.10.2025 - Goldman Sachs Annual Global Healthcare Conference
• 06.10.2025 - Goldman Sachs Annual Global Healthcare Conference
• 05.27.2025 - Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
• 05.27.2025 - Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
• 05.21.2025 - Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors
• 05.21.2025 - Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors
• 05.12.2025 - Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
• 05.12.2025 - Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
• 05.01.2025 - Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
• 05.01.2025 - Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

Recent Filings

• 05.21.2025 - EFFECT Notice of Effectiveness
• 05.12.2025 - S-3 Registration statement under Securities Act of 1933
• 05.12.2025 - 8-K Current report
• 05.12.2025 - EX-99.1 EX-99.1
• 05.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 04.24.2025 - DEFR14A Revised definitive proxy soliciting materials
• 04.22.2025 - ARS Annual Report to Security Holders
• 04.22.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.21.2025 - DEF 14A Other definitive proxy statements
• 04.11.2025 - PRE 14A Other preliminary proxy statements